Scholarly Index
Sung‐Bae Kim
University of Ulsan; 41,838 total citations; 618 total publications; best world rank #22
University of Ulsan
41,838Total citations
618Total publications
74H-index
Published ranking records
| Field | Window | World rank | National rank | Impact score |
|---|---|---|---|---|
| Cancer Treatment and Pharmacology | Lifetime | 192 | KR 3 | 99.40 |
| HER2/EGFR in Cancer Research | Lifetime | 160 | KR 4 | 99.23 |
| Advanced Breast Cancer Therapies | Lifetime | 107 | KR 2 | 99.00 |
| Esophageal Cancer Research and Treatment | Lifetime | 300 | KR 3 | 98.27 |
| Breast Cancer Treatment Studies | Lifetime | 567 | KR 12 | 98.31 |
| Head and Neck Cancer Studies | Lifetime | 893 | KR 14 | 96.88 |
| Chemotherapy-related skin toxicity | Lifetime | 690 | KR 8 | 83.44 |
| HER2/EGFR in Cancer Research | 2021-2025 | 22 | KR 2 | 99.50 |
| Cancer Treatment and Pharmacology | 2021-2025 | 25 | KR 2 | 99.52 |
| Advanced Breast Cancer Therapies | 2021-2025 | 38 | KR 3 | 99.26 |
| Breast Cancer Treatment Studies | 2021-2025 | 121 | KR 5 | 98.43 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 188 | KR 2 | 96.42 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 754 | KR 25 | 97.12 |
| Esophageal Cancer Research and Treatment | 2021-2025 | 263 | KR 8 | 94.99 |
| Cancer-related Molecular Pathways | 2021-2025 | 607 | KR 22 | 77.98 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 311 | KR 8 | 77.07 |
| PARP inhibition in cancer therapy | 2021-2025 | 841 | KR 21 | 80.00 |